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Abstract: The development of high-performance contrast agents in magnetic resonance imaging 
(MRI) has recently received considerable attention, as they hold great promise and potential as a 
powerful tool for cancer diagnosis. Despite substantial achievements, it remains challenging to 
develop nanostructure-based biocompatible platforms that can generate on-demand MRI signals 
with high signal-to-noise ratios and good tumor specificity. In this article, we report the design and 
synthesis of a new class of nanoparticle-based contrast agents comprising self-assembled NaGdF4 
and CaCO3 nanoconjugates. In our design, the spatial confinement of the T1 source (Gd
3+ ions) 
leads to an “OFF” MRI signal due to insufficient interaction between the protons and the crystal 
lattices. However, when immersed in a mildly acidic tumor microenvironment, the embedded 
CaCO3 nanoparticles generate CO2 bubbles and subsequently disconnect the nanoconjugate, thus 
resulting in an “ON” MRI signal. The in vivo performance of this nanoconjugates shows more than 
60-fold contrast enhancement in tumor visualization relative to commercially used contrast agent 
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Magnevist. Our work presents a significant advance in the construction of smart MRI nanoprobes 
ideally suited for deep-tissue imaging and target-specific cancer diagnosis. 
 
Magnetic resonance imaging (MRI) is a powerful technique for noninvasive disease diagnosis 
and therapeutic monitoring. MRI can provide invaluable details of anatomical structures, which 
stem from the subtle interactions between water protons and biomolecules in surrounding tissues.[1-
4] However, MRI images often suffer from poor spatial resolution due to limited differences 
between dynamic microenvironments in healthy and diseased tissues.[5,6] Therefore, exogenous 
agents are generally required to enhance the contrast and enable the differentiation of anatomical 
lesions from healthy tissues.[7-9] MRI contrast agents are classically divided into two categories 
based on the imaging modalities, where longitudinal and transversal relaxation time of protons is 
shortened, resulting in positive or negative signal enhancements in T1- or T2-weighted MRI, 
respectively, when an appropriate pulse sequence is applied.[10,11] The well-established positive 
contrast agents generally contain inorganic nanoparticles or organic complexes fused with metal 
ions, such as gadolinium (Gd3+),[12,13] iron,[14-16] or manganese.[17,18] The past decade has witnessed 
the widespread use of Gd3+-based chelation complexes (e.g., Magnevist) as clinical imaging agents, 
primarily due to their excellent contrast enhancement and negligible immunogenicity. Gd3+ 
essentially holds an electronic relaxation rate of 6 orders of magnitude slower than other lanthanides 
because of its seven unpaired electrons occupying at the ground state (8S7/2),
[19] which makes Gd3+ 
suitable as an excellent T1-source. However, Gd
3+-based commercial agents have two severe 
limitations: short circulating time and lack of specificity in vivo. These drawbacks inevitably lead to 
low signal-to-noise ratios (SNR), an increased risk of Gd3+ retention and the need for high dose 
regimes. 
To address these issues, considerable efforts have been devoted to the development of Gd3+-
based inorganic nanoparticles featuring different morphologies, sizes, and surface functional 
groups.[20-22] Given the extensive exposure of Gd3+ ions, ultrasmall Gd3+-based nanoparticles are 
characterized with ideal longitudinal relaxivity.[23] However, they are restricted by their short-time 
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circulation in the blood due to fast renal clearance, which hinders their utility in real-time tracking 
and visualization of lesions. Recently, CaCO3 and CaPO4 nanoparticles have been used as host 
materials for pH sensing and controlled release of manganese ions and drugs at tumor sites.[24,25] In 
addition, nanostructures assembled by magnetic nanoparticles have emerged as negative contrast 
agents for MRI.[26-28] We reasoned that self-assembled NaGdF4-CaCO3 nanoconjugates that could 
be encapsulated by cell membrane cloaking would provide an all-in-one MRI nanoplatform with 
high tumor selectivity and good biocompatibility (Figure 1a). 
In our design, we hypothesized that the MRI imaging signals of NaGdF4-CaCO3 
nanoconjugates would be initially blocked because of the structural separation of NaGdF4 
nanoparticles from water protons, and subsequently recovered under acidic conditions due to the 
CO2-triggered release of NaGdF4 nanoparticles. In the presence of activated T1 source, the protons 
in resonance with the radiofrequency can rapidly relax to their initial spin state with a recovery of 
the net magnetization aligned to the direction of the magnetic field (MZ) (Figure 1b). Therefore, 
NaGdF4 nanoparticles released from the nanoconjugates facilitate the energy transfer from protons 
to Gd3+ ions through spin-lattice interaction, leading to a shortened longitudinal relaxation time, 
faster recovery of MZ and ultimately brighter images. 
To verify our hypothesis, ultrasmall NaGdF4 nanoparticles with an average size of 3.6 nm were 
first synthesized via a co-precipitation method (Figure S1).[29] Then, we prepared CaCO3 
nanoparticles (~18 nm) that were highly responsive to a mildly acidic environment by a gas 
diffusion reaction (Figure S2).[24] The mixture of NaGdF4 nanoparticles and PLGA in 
dichloromethane was added into a flask containing Pluronic F-127 and CaCO3 nanoparticles in 
deionized water. The hydrophobic interaction between nanoparticles and polymers resulted in the 
formation of milky white emulsion after 5 minutes of sonication. Uniform bare self-assembled 
nanoparticles (BSNPs) were generated by adding branched polyethylenimine (PEI), followed by 
overnight agitation at room temperature to evaporate the organic solvent (Figure 2a). Statistical 
analysis of the transmission electron microscopy (TEM) images showed a mean particle diameter of 
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142 nm with a narrow size distribution (Figure S3a). X-ray powder diffraction and energy 
dispersive X-ray spectroscopy indicated the presence of NaGdF4 and CaCO3 nanoparticles inside 
BSNPs (Figures S4 and S5). An essential advantage of using branched PEI is to facilitate the 
formation of homogeneous BSNPs by suppressing the recombination of emulsion droplets (Figure 
S6). The positively charged PEI layer also facilitated the cloaking of negatively-charged cell 
membranes onto the surface of BSNPs due to their electrostatic interaction and the formation of 
amide bonds between branched PEI and phospholipids or proteins (Figure S7).[30] TEM imaging 
analysis showed the average diameter of cell membrane coated-BSNPs (MSNPs) was 191 nm 
(Figure 2b,c and Figure S3b).  
To further validate the successful coating of NaGdF4–CaCO3 nanoconjugates with membranes 
derived from HeLa cells, we labeled BSNPs and HeLa cell membranes with green-fluorescent 
fluorescein isothiocyanate (FITC) and red-fluorescent anti-p-Cadherin antibody, respectively. This 
protocol allowed us to observe overlay images of green and red emissive spots from membrane-
coated nanostructures under luminescence microscopy (Figure 2d). In contrast, BSNPs showed only 
green emission spots (Figure 2e). The successful membrane coating was also confirmed by dynamic 
light scattering and zeta potential measurements. As shown in Figure 2f, the hydrodynamic size of 
BSNPs increased from ~178 to ~215 nm after coating. In addition, the zeta potential of MSNPs 
turned negative, which contrasts with the positive value of BSNPs (Figure 2g). Moreover, the 
potential observed for MSNPs (-24 mV) was very similar to pure HeLa cell membranes, indicating 
that the HeLa cell membranes fully covered the surface of MSNPs.[31-33] To verify the biomimetic 
functionality of the decorated MSNPs, we also measured the concentration of p-Cadherin in BSNPs 
and MSNPs by ELISA (enzyme-linked immunosorbent assay).[34] The observed high levels of p-
Cadherin in MSNPs but not in BSNPs indicated a similar surface configuration for MSNPs when 
compared to HeLa cell membranes (Figure 2h). 
We further investigated the structural stability of MSNPs. To our delight, we detected no 
apparent changes in the morphology of MSNPs that were stored under phosphate buffer solution 
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(pH 7.4) for up to two weeks (Figure S8). The dynamic light scattering measurement also showed a 
negligible increase in hydrodynamic size (Figure S9), which confirmed the high stability of MSNPs. 
In contrast, BSNPs exhibited a marked change in both the hydrodynamic size and the shape under 
identical experimental conditions. Taken together, the improved structural stability of MSNPs over 
BSNPs can be attributed to the cloaking of nanostructures with cell membranes. 
We next tested the suitability of CaCO3 nanoparticles embedded in MSNPs as pH sensors in 
response to the acidic environment found in most tumors. As illustrated in Figure 3a, encapsulated 
CaCO3 nanocrystals can generate CO2 bubbles in situ under mildly acidic conditions, which leads to 
the rapid disintegration of the self-assembled nanoconjugates. In our in vitro experiments with 
different pH buffer solutions, we observed that the surface membrane started disassembling at pH 6 
(Figure 3b), and the nanoconjugates were fully disintegrated at pH 5. A similar pH response was 
also observed for BSNPs (Figure S10). 
We also performed negative control experiments by synthesizing self-assembled 
nanostructures without incorporating CaCO3 nanoparticles to demonstrate that multilayered 
structures remained intact in neutral and mildly acidic conditions (Figures S11 and S12). Notably, 
in contrast to MSNPs, the morphology of BSNPs containing CaCO3 nanoparticles did not remain 
uniform, and their structure appeared to be unstable (Figure S13). This observation highlights that 
the ratio of NaGdF4 to CaCO3 is a key factor to achieve an optimal balance between structural 
stability at neutral pH and in situ activation in acidic microenvironments. 
To verify the feasibility of using MSNPs as smart contrast agents with high sensitivity to the 
acidic microenvironment in tumors, we monitored their longitudinal relaxivity changes in vitro 
under different conditions. The longitudinal relaxivity (r1) of MSNPs was relatively low (0.79 mM
-
1s-1) at neutral pH (Figure 3c), whereas its r1 value sharply increased in acid media, with an over 10-
fold increase from pH 7.4 to 5.0. The corresponding T1-weighted phantom images (Figure 3d) also 
showed a significant improvement of the contrast signals when the solutions became acidic. At the 
beginning, water protons only directly interact with limited NaGdF4 nanoparticles which are located 
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at the outer layer of the nanoconjugates. When water protons react with CaCO3 from the outside to 
inside, NaGdF4 nanoparticles at the same layers could be simultaneously released through a layer-
by-layer exfoliation. The large amount of the released ultra-small NaGdF4 nanoparticles results in a 
significant MRI signal enhancement, while the initial form of nanoconjugates with inefficient 
interaction with protons gives a limited signal enhancement. In addition, we performed the same 
experiments in BSNPs and observed good relaxivity and contrast enhancement in vitro (Figure S14). 
This observation highlights that the HeLa cell membrane layer has no significant effect on the 
sensitivity of BSNPs to acid microenvironments or the release of NaGdF4 nanoparticles. 
We measured the cytotoxicity of BSNPs and MSNPs in different cell lines (RAW 264.7, NIH 
3T3 and HeLa cells) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay. In all cases, cell viabilities were over 80 %, even when using concentrations of 
BSNPs and MSNPs at 200 µg/mL (Figure S15), which indicates good biocompatibility. Next, we 
examined the specific targeting properties of MNSPs to homogenous HeLa cells by flow cytometry 
experiments. MSNPs exhibited preferential uptake in HeLa cells (Figure 3e,h), while both BSNPs 
and MSNPs presented relatively low cellular uptake in HepG2 cells (Figure 3f,i), highlighting the 
homogenous tumor-targeting capabilities of MSNPs. To better understand the active uptake of 
MSNPs in HeLa cells, we compared their internalization in untreated cells and in cells pre-treated 
with cytochalasin D, a potent inhibitor of actin polymerization that blocks active transport. We 
observed that the uptake of MSNPs by HeLa cells was blocked to the levels of BSNPs (Figure 3g,j). 
This result suggests that cell surface recognition is essential to facilitate the active internalization of 
MSNPs in HeLa cells. 
To validate the MRI contrast enhancement effect at the cellular level, we also acquired T1-
weighted MRI phantom images of HeLa cells microgel solutions containing PBS buffer, BSNPs or 
MSNPs. As shown in Figure 3k, we demonstrated that remarkably brighter phantom images with 
significantly enhanced positive contrast were obtained from Hela cells that had been incubated with 
MSNPs but not with BSNPs or in the PBS control group, validating the active internalization of 
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MSNPs and the release of NaGdF4 nanoparticles in HeLa cells. Finally, we also assessed the half-
life of both BSNPs and MSNPs by tracking the content of Gd3+ ions in venous blood samples via 
inductive coupled plasma-optical emission spectroscopy. The results indicate that the HeLa cell 
membrane coating endows a prolonged in vivo circulation time (Figure S16), which enhances the 
targeting properties of MSNPs by the enhanced permeability and retention effect. 
The promising in vitro performance of MSNPs prompted us to investigate their contrast 
capabilities in vivo. As a proof-of-concept, we prepared subcutaneous tumor-bearing mice with 
HeLa cells transplants to study the behavior of MSNPs in animal models. T1-weighted MR images 
were acquired in vivo before and after intravenous injection of MSNPs. The tumor site appeared as 
dark before the injection of MSNPs and started lighting up approximately 30 min post-injection 
(Figure 4a,c and Figure S17). The contrast enhancement at the tumor site reached a tumor-to-
background (T/B) ratio of ~48 at 195 min post-injection when the entire tumor was lighted up. Next, 
Magnevist, a representative of clinical contrast agents, was chosen as a control contrast agent due to 
its widespread use for clinical applications and its facile accessibility. We injected Magnevist 
intravenously and monitored its accumulation over time. In contrast to MSNPs, the entire body, 
including tumor site, muscles, and especially the bladder, were lighted up after 30 min post-
injection (Figure 4b and Figure S17). The bright signals from the bladder also confirmed the fast 
renal clearance and urinary excretion of Magnevist. These results suggest that, although Magnevist 
represents a good candidate for contrast enhancement in whole-body imaging, its limited targeted 
specificity may compromise its application for in vivo tumor visualization.25 Importantly, 
quantitative image analysis of the regions of interest indicated that tumor-to-muscle (T/M) ratios 
were 61.6-fold higher for MSNPs when compared to Magnevist (Figure 4d). 
To assess any in vivo cytotoxicity of MSNPs, hematoxylin and eosin (H&E) staining of several 
organs was carried out after MSNP injection. The histology results showed no acute (6 h) or chronic 
(2 weeks) tissue injuries in the heart, liver, spleen, lungs or kidneys after administration of MSNPs 
(Figure S18). Longitudinal tracking of MSNPs in these organs (Figure S19) showed accumulation 
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of MSNPs at the tumor sites up to 1.5 h post-injection (about 12 % ID/g), which concurs with their 
enhanced circulation time. This result also confirms the targeting effect of MSNPs, indicative of 
their high performance in terms of tumor visualization. Body weight monitoring and biochemical 
tests showed no in vivo cytotoxicity of MSNPs (Figures S20 and S21). 
In summary, we have developed a smart MRI contrast nanoconjugate based on a combination 
of NaGdF4 and CaCO3 nanoparticles. The efficient isolation of Gd
3+ ions from water protons 
enabled by the rigid framework of the nanoconjugate leads to a silent T1 signal. The silent mode of 
T1 signal can be readily turned on in acidic conditions, where self-assembled nanoconjugate rapidly 
break apart due to the in-situ generation of CO2 and concomitant release of NaGdF4 nanoparticles. 
Surface coating of the nanoconjugate with biomimetic cell membranes resulted in a substantial 
increase in circulation lifetime and tumor-targeting capabilities in vivo. The development of 
NaGdF4–CaCO3 nanoconjugates may revolutionize the study of tumor imaging in vivo by providing 
pH-responsive MRI contrast agents that are more sensitive and selective than those currently in 
clinical practice. 
 
Experimental Section   
The experimental details are provided in the Supporting Information. 
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Figure 1. Schematic diagram showing the rationally-designed MSNPs as smart contrast agents for 
T1-weighted MRI. (a) The synthetic diagram of MSNPs. (i) Membrane extraction from live HeLa 
cells. (ii) Assembling BSNPs using nanoparticles (NaGdF4 and CaCO3) as building blocks and 
polymers (PLGA, Pluronic F127 and branched PEI) as linkers. (iii) Cloaking cell membranes onto 
the surface of BSNPs. (b) Schematic illustration of the variation in relaxation time of protons upon 
blocking and activating T1 source (ultrasmall NaGdF4 nanoparticles). With an external steady-state 
magnetic field B0, the spin of protons reaches a steady-state under radiofrequency (MZ = 0, upper 
left panel). The spin state of protons recovers to the initial state (MZ = M0) after the radiofrequency 
disappears. The recovery is facilitated when the T1-source is activated, and the corresponding 
longitudinal relaxation time is shortened (upper right panel), resulting in a bright image. Basically, 
in this design, the spin interaction between crystal lattices and surrounding protons is structurally 
blocked by multilayers outside the T1 source (blue line). The energy transfer (ET) from protons to 
crystal lattices via spin-lattice interaction is then activated due to the pH-responsive capability of 
MSNPs under acidic microenvironments (orange line). 
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Figure 2. Synthesis and structural characterization of prepared BSNPs and MSNPs. Typical TEM 
images of BSNPs (a) and MSNPs (b,c). The luminescence microscopy images of MSNPs (d) and 
BSNPs (e) after treated with FITC salt and anti-p-Cadherin antibody in sequence. (f) Hydrodynamic 
size, (g) zeta potential and (h) ELISA quantitative assays by tracking the amounts of p-Cadherin on 
the surface of HeLa cells, BSNPs and MSNPs. Note that cytosolic protein in h is used as negative 
control. Values in (f-h) represented as means ± s.d. (n = 3). 
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Figure 3. In vitro activation of MSNPs. (a) Schematic illustration showing structure disruption of 
MSNPs in acidic conditions. The reaction formula indicates the generation of carbon dioxide 
bubbles, which promote the disintegration of nanostructures and the release of NaGdF4 
nanoparticles to facilitate spin-lattice interactions between NaGdF4 nanoparticles and water protons. 
(b) Typical TEM images of MSNPs cultured in PBS buffer solutions with different pH values (6.0, 
5.5, 5.0) for 10 min. (c) The plots showing a linear relationship of longitudinal relaxivity of MSNPs 
versus the concentration of Gd3+ ions. (d) The corresponding in vitro T1-weighted MRI phantom 
images of the solution containing MSNPs in PBS buffer with different pH values. (e,h) Flow 
cytometry profiles and the corresponding cellular uptake calculation of HeLa cells cultured with 
BSNPs or MSNPs (0.25 µg/mL FITC). (f,i) Flow cytometry profiles and the corresponding cellular 
uptake calculation of HepG2 cells cultured with BSNPs or MSNPs (0.25 µg/mL FITC). (g,j) Flow 
cytometry profiles and histograms showing FITC intensity of HeLa cells cultured with MSNPs 
without or with the addition of cytochalasin D (CD, 10 µL, 5 µg/mL). (k) In vitro T1-weighted MRI 
phantom images of HeLa cells microgel solutions pre-treated with pure PBS, BSNPs and MSNPs, 
respectively. Values represented as means ± s.d. (n=3). 
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Figure 4. Positive contrast enhancement evaluation in vivo. T1-weighted MRI and corresponding 
pseudocolor images of tumor-bearing mice after intravenous injection of (a) MSNPs and (b) 
Magnevist with the same dosage (2.5 µmol of Gd3+ for each mouse). Images were captured before 
and at different time points after the administration of contrast agents. Dotted circles represent the 
regions of interest: (1) tumor, (2) muscle, (3) background, (4) bladder. Scale bars are 5 mm for all 
images. The small spots on the corners are from the circulation apparatus in the MRI scanner. (c,d) 
Tumor-to-background (T/B) and tumor-to-muscle (T/M) contrast ratios based on the corresponding 
MRI images. Values represented as means ± s.d. (n = 3). 
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Commercially available contrast agents, such as Magnevist, for T1-weighted MRI suffer from short 
in vivo circulating time and a lack of specific targeting to tumor, which hampers their applications 
in high-performance bioimaging and cancer diagnosis. To this regard, a smart contrast agent 
comprising cancer cell membranes cloaked NaGdF4–CaCO3 nanoconjugates is designed for 
amplifying the MRI signal on demand through its sensitive response to mildly acidic tumor 
microenvironment. 
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